ORN-101

N/A

Report date: 2026/05/13 09:17:21

Base Information

Drug NameORN-101
Drug Alias NameORN-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNPSmall molecules > Nucleosides and nucleotide derivtives > Circular RNACell and gene therapy > Gene therapy > LNP +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOrna Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrna Therapeutics IncShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A